Pipeline

Building superior ADCs

Iksuda ADCs are designed for maximum anti-cancer impact and enhanced therapeutic index, targeting patient sub-groups that are currently poorly-treated.

Our lead programmes target solid tumours including ovarian, lung, pancreas, cervix and renal cell carcinoma.

The first wave of Iksuda ADCs will target antigens that have proven premise in an ADC format with our next-wave focussing on novel antigen targets.

IKS01

Solid tumors
Pre-clinical – 100%

IKS02

Solid tumors
Research/Discovery – 100%

IKS03

Solid tumors
Research/Discovery – 100%

IKS04

Solid tumors
Research/Discovery – 100%